Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial.

Jessica A WalshMarina N MagreyXenofon BaraliakosKentaro InuiMeng-Yu WengEnnio LubranoDésirée van der HeijdeAnnelies BoonenLianne S GenslerVibeke StrandJürgen BraunTheresa Hunter GibbleXiaoqi LiBaojin ZhuLuis LeónDavid Marcelino Sandoval CalderonUta Kiltz

Published in: Arthritis care & research (2020)

Ixekizumab was superior to placebo improving self-reported functioning and health in patients with nr-axSpA at Weeks 16 and 52.

Keyphrases

public health
healthcare
mental health
phase iii
health information
clinical trial
study protocol
ankylosing spondylitis
randomized controlled trial
disease activity
placebo controlled
double blind
rheumatoid arthritis
open label
gestational age
systemic lupus erythematosus